Anticoagulants Market to extend at $43,427 Million, with a growing CAGR by 2025

The Anticoagulants Market was valued at $24,265 million in 2017, and is predicted to grow at $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025.

The global anticoagulants industry is anticipated to show significant growth during the forecast period, owing to increasing prevalence of venous thromboembolism (VTE) and cardiovascular disorders, growing adoption of novel oral anticoagulants (NOACs), and rising awareness of NOACs in the developing region. Furthermore, increase in number of obese and elderly people, higher unmet needs, and surge in demand of novel therapeutics further support the market growth. However, higher price of NOACs and lack of antidots for NOACs impede the market growth.

Download Sample Report @ https://www.alliedmarketresearch.com/request-sample/1673?utm_source=opr_sank

Anticoagulant drugs (also known as blood thinners) are chemical substances that prevent or reduce coagulation of blood and prolong the blood clotting time. These drugs are majorly used for high risk of blood clots in various medical conditions, such as atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others.

Anticoagulants Market Segmentation

The global anticoagulants market is segmented based on drug class, route of administration, application, and region. On the basis of drug class, the anticoagulants market is classified as NOACs, heparin and LMWH, vitamin K antagonist, and others. By route of administration, the market is segmented as oral anticoagulant and injectable anticoagulant. The various application markets are atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others. Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

On the basis of drug class, the anticoagulants market is segmented as NOACs, heparin & LMWH, vitamin K antagonist, and others. At present, the NOACs segment is a major revenue-generating segment and is anticipated to show dominance during the forecast period, owing to growing awareness of NOACs and rising use of NOACs over the warfarin. However, higher price of NOACs hinders the market growth. As per the route of administration, the anticoagulants market is segmented as oral anticoagulant and injectable anticoagulant. At present, the oral anticoagulant segment is a major revenue-generating segment and is anticipated to show dominance during the forecast period, owing to growing adoption of NOACs and rising availability of lower cost warfarin.

The application market is categorized as atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others. Presently, the atrial fibrillation & heart attack segment is a major revenue contributor and is anticipated to show dominance throughout the forecast period, owing to large target population and increase in use of anticoagulants to treat these conditions. However, the DVT segment is expected to show the fastest market growth, attributed to the increase in prevalence of DVT and technological advancement in diagnosis of DVT.

Key Findings of the Anticoagulants Market:

• As per the drug class, the NOACs segment is expected to show the fastest market growth and grow at a CAGR of 8.0% from 2018 to 2025.
• On the basis of the route of administration, the oral anticoagulant segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
• By application, the deep vein thrombosis (DVT) segment is expected to exhibit the fastest growth at a CAGR of 8.4% from 2018 to 2025.
• Region-wise, the Asia-Pacific region is expected to experience growth at the highest rate, registering a CAGR of 9.2% during the forecast period.

North America accounted approximately one-half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. This was attributed to the higher demand for novel therapeutics, strong presence of key players, early diagnosis, developed healthcare infrastructure, presence of trained medical professionals, and larger target population. However, the Asia-Pacific region is expected to experience the highest growth rate during the forecast period, majorly owing to improving healthcare infrastructure with developing economies, rising diagnosis rate, enhancing health awareness, and increasing prevalence of cardiovascular disease and VTE.

Flat 20% Discount on All License Type.. https://www.alliedmarketresearch.com/checkout/980005
*Offer Valid Till 20th April 2019

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client's insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.